Education
About Us
Working with TipRanks
Follow Us
Gilead Sciences (GILD)
NASDAQ:GILD
Earnings Data
Report Date
Apr 23, 2026After Close (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
1.9Last Year’s EPS
1.81Same Quarter Last Year
Moderate Buy
Based on 21 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call emphasized strong commercial execution (notably in HIV treatment and prevention, liver, and Trodelvy) and a robust, diversified late-stage pipeline with multiple near-term catalysts and disciplined financial management. These positives were balanced against clear near-term headwinds: policy-driven pricing impacts (Part D/Medicaid/ACA), a substantial decline in COVID-related Vecluri revenue, and competitive pressures in cell therapy expected to reduce Kite revenues in 2026. Management reiterated conservative discipline on M&A and continued commitment to shareholder returns. Overall, company achievements, pipeline momentum, and outperformance against guidance materially outweigh the headwinds, which are largely known, quantified, and described as manageable.Company Guidance
Strong HIV Franchise Growth and Market Leadership
HIV business grew 6% year-over-year in 2025 (driven by Biktarvy +7%), with full-year HIV sales of $20.8 billion. Biktarvy full-year sales were $14.3 billion, up 7% YoY and remains >52% share in the U.S. switch/treatment market. Company noted that excluding an estimated ~ $900M Part D headwind, HIV growth would have been ~10% in 2025.
Robust HIV Prevention Momentum (YES2GO & Descovy)
YES2GO launch exceeded coverage goals (90% payer coverage and ~90% of covered individuals with $0 copay). YES2GO sales: $96M in Q4 and $150M for full-year 2025; management guides ~ $800M revenue for YES2GO in 2026. HIV prevention momentum: Q4 prevention sales grew ~53% YoY; Descovy full-year sales $2.8B, up 31% YoY (Q4 Descovy +33% YoY; Descovy accounts for ~80% of its sales from prevention).
Overall Revenue and Base Business Outperformance
Full-year total product sales were $28.9 billion (up 1% YoY). Base business (excluding Vecluri) was $28.0 billion, more than $300 million above the high end of guidance and up ~4% YoY (or ~8% excluding Medicare Part D redesign impact). Q4 product sales excluding Vecluri were $7.7 billion, +7% YoY and +9% sequentially.
Strong Liver and Trodelvy Performance
Liver business grew 6% YoY to $3.2 billion in 2025. Libdelzi showed strong adoption: Q4 Libdelzi sales were $150M (a 42% sequential increase) and U.S. market share leader >50% in second-line PBC. Trodelvy full-year sales grew 6% to $1.4 billion; Q4 sales $384M, +8% YoY and sequentially.
Clinical & Pipeline Momentum — Multiple Near-Term Catalysts
Company highlighted a ‘‘catalyst-rich’’ 2026 with multiple Phase III readouts and up to four potential commercial launches (Trodelvy first-line TNBC, Viclen (bictegravir+lenacapavir), Anidocel, and bruleviratide). Management emphasized up to 10 potential launches through 2027 and 53 ongoing clinical programs, and positive Phase III readouts already published (e.g., Trodelvy ASCENT-03/04 in NEJM and NCCN guideline recognition).
Solid Profitability and Capital Returns
Non-GAAP product gross margin was 86.4% (in line with guidance). Full-year non-GAAP operating margin ~45% (roughly 48% excluding acquired IPR&D and a $400M one-time item). Non-GAAP diluted EPS was $8.15 for 2025; excluding ~$3.14/share Simbae impact, EPS increased by $0.40 vs 2024. Returned $5.9 billion to shareholders in 2025 and returned ~63% of free cash flow to shareholders (dividends + buybacks).
Kite/Anidocel: Highly Differentiated Clinical Data
Anidocel (BCMA CAR-T) data from Phase II IMagine I: 96% overall response rate, 74% complete response, and 95% MRD negativity with a predictable/manageable safety profile. Anidocel filing submitted and company is preparing for potential H2 2026 launch (modest 2026 contribution expected with larger 2027 opportunity).
GILD Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
GILD Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Feb 10, 2026 | $147.23 | $155.80 | +5.82% |
Oct 30, 2025 | $117.66 | $119.00 | +1.14% |
Aug 07, 2025 | $108.80 | $117.81 | +8.28% |
Apr 24, 2025 | $103.99 | $101.07 | -2.81% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Gilead Sciences (GILD) report earnings?
Gilead Sciences (GILD) is schdueled to report earning on Apr 23, 2026, After Close (Confirmed).
What is Gilead Sciences (GILD) earnings time?
Gilead Sciences (GILD) earnings time is at Apr 23, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is GILD EPS forecast?
GILD EPS forecast for the fiscal quarter 2026 (Q1) is 1.9.